DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Sanderling Management Company, LLC
Sanderling Management Company, LLC
Institutional venture firmSan Mateo, CAsanderling.comSEC venture capital fund adviserfundraising evidence
Sanderling has supported over 90 biomedical companies earning consistently high rates of return on its venture investments.
venture manager, reported GAV $177M across 23 vehicles
Importance
43
elevated
Active deployment
90
high
Emerging
0
low
Completeness
75
high
Freshness
100
high
Research priority
28
moderate
Identity and regulatory footprint
- Headquarters
- San Mateo, CAadviserinfo.sec.gov
- Office address
- 1900 S NORFOLK ST, SUITE 215, San Mateo, CA, 94403-1172adviserinfo.sec.gov
- Business phone
- 650 401 2000adviserinfo.sec.gov
- Website
- HTTP://WWW.SANDERLING.COM/
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 31, 2026
- Private funds reported
- 8 (8 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $161Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- business email
- info@sanderling.comsanderling.compublished by the subject
- business phone
- 650 401 2000adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
37 observed deals
Stated (the firm’s website)
- Sectors
- biotech, medtech
- Stages
- early
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 100%
lead rate n/afollow-on rate n/anew logos, 12 months 37
Funds and vehicles
23 reported, 7 no longer reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| MHS Capital Partners IN, LLC | Fund | 2026 form d first sale | Newly closed | unknown | unknown | $4.0M of $4.0M | May 7, 2026 |
| MHS Capital Partners ST, LLC | Fund | 2026 form d first sale | Newly closed | unknown | unknown | $8.5M of $8.5M | May 7, 2026 |
| MHS Capital Partners CE, LLC | Fund | 2026 form d first sale | Newly closed | unknown | unknown | $3.0M of $3.0M | May 7, 2026 |
| Neo SPV 4.3, LP | SPV or co-invest vehicle | 2025 form d first sale | Newly closed | unknown | unknown | $6.0M of $6.0M | Nov 4, 2025 |
| Neo SPV 4.4, LP | SPV or co-invest vehicle | 2025 form d first sale | Newly closed | unknown | unknown | $26.9M of $26.9M | Dec 22, 2025 |
| Sanderling Ventures VII Annex Fund, LP | Continuation vehicle | 2017 adv first reported | Harvest | $3.6M Mar 30, 2024 | 7 | $0 of $10.0M | Jul 5, 2016 |
| Sanderling Ventures VII (canada), L.P. | Fund | 2014 adv first reported | Harvest | $20.1M Mar 30, 2024 | 3 | unknown | unknown |
| Sanderling Ventures VII, L.P. | Fund | 2013 adv first reported | Harvest | $81.1M Mar 30, 2024 | 30 | unknown | unknown |
| Sanderling Ventures Partners VI Co-Investment Fund, L.P. | SPV or co-invest vehicle | unknown | Unknown | $27.9M Mar 30, 2024 | 63 | unknown | unknown |
| Sanderling Venture Partners VI, L.P. | Fund | unknown | Unknown | $13.3M Mar 30, 2024 | 73 | unknown | unknown |
| Sanderling V Strategic Exit Fund, L.P. | Fund | unknown | Unknown | $10.6M Mar 30, 2024 | 11 | unknown | unknown |
| Sanderling Venture Partners V, L.P. | Fund | unknown | Unknown | $8.6M Mar 30, 2024 | 47 | unknown | unknown |
| Sanderling Venture Partners V Co-Investment Fund, L.P. | SPV or co-invest vehicle | unknown | Unknown | $5.8M Mar 30, 2024 | 29 | unknown | unknown |
| Sanderling V Biomedical Co-Investment Fund, L.P. | SPV or co-invest vehicle | unknown | Unknown | $3.5M Mar 30, 2024 | 6 | unknown | unknown |
| Sanderling V Biomedical, LP | Fund | unknown | Unknown | $1.3M Mar 30, 2024 | 7 | unknown | unknown |
| Sanderling V Limited Partnership | Fund | unknown | Unknown | $402,817 Mar 30, 2024 | 16 | unknown | unknown |
| Sanderling V Beteiligungs Gmbh & Co. Kg | Fund | unknown | Unknown | $383,804 Mar 30, 2024 | 8 | unknown | unknown |
| Sanderling VI Limited Partnership | Fund | unknown | Unknown | $170,766 Mar 30, 2024 | 15 | unknown | unknown |
| Sanderling VI Beteiligungs Gmbh & Co. Kg | Fund | unknown | Unknown | $152,274 Mar 30, 2024 | 3 | unknown | unknown |
| Sanderling IV Limited Partnership | Fund | unknown | Unknown | $42,001 Mar 30, 2024 | 28 | unknown | unknown |
| Wavepeak Ventures Fund I, LP | Fund | unknown | Fundraising | unknown | unknown | $0 of $50.0M | Nov 4, 2025 |
| Health Velocity Capital III Executive Network Fund, L.P. | Fund | unknown | Fundraising | unknown | unknown | $0 of $15.0M | Mar 24, 2026 |
| Health Velocity Capital III, L.P. | Fund | unknown | Fundraising | unknown | unknown | $0 of $300M | Dec 17, 2025 |
| Revelation-Sanderling, LLC | Fund | 2016 adv first reported | Wound down | $0 Apr 3, 2023 | 3 | unknown | unknown |
| Sanderling Venture Partners II, L.P. | Fund | unknown | Wound down | $641,403 Oct 25, 2012 | 52 | unknown | unknown |
| Sanderling IV Biomedical Co-Investment Fund, L.P. | SPV or co-invest vehicle | unknown | Wound down | $207,505 Apr 3, 2023 | 5 | unknown | unknown |
| Sanderling IV [feri Trust] Venture Partners | Fund | unknown | Wound down | $46,793 Apr 3, 2023 | 10 | unknown | unknown |
| Sanderling IV Biomedical, L.P. | Fund | unknown | Wound down | $17,621 Apr 3, 2023 | 8 | unknown | unknown |
| Sanderling Venture Partners IV, L.P. | Fund | unknown | Wound down | $0 Apr 3, 2023 | 47 | unknown | unknown |
| Sanderling Venture Partners IV Co-Investment Fund, L.P. | SPV or co-invest vehicle | unknown | Wound down | $0 Apr 3, 2023 | 3 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
5 current, 4 departed
Robert G. Mcneil
Managing partnerFounding Partner (September 4, 1943 – July 23, 2021)
Frederick Alexander Middleton
PartnerManaging Director · since Dec 1, 1987
Timothy Curtis Mills
PartnerManaging Director · since Jan 1, 2000
Timothy Mills
PartnerManaging Director
Pierre Beauparlant
Venture partnerVenture Partner
4 departed (kept with end dates)
- Robert G. McNeil · Founding Partner (September 4, 1943 – July 23, 2021) · ? to Sep 16, 2026 Inference
- Peter C. M. Macwilliams · Managing Director · Dec 1, 2017 to Apr 29, 2020 Inference
- Robert Gordon Mcneil · Managing Director · Dec 1, 1987 to Apr 4, 2022 Inference
- Timothy Mills · Managing Director · ? to Sep 16, 2026 Inference
Investments on record
37 edges, 37 companies, 0 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
7 relationships from shared deals, counted for the whole firm
Revival Healthcare Capital LLC 1 shared · one timeArtis Ventures Management, L.P. 1 shared · one timeMission Biocapital 1 shared · one timeRHO Capital Partners 1 shared · one timeArtis Capital Management, L.P. 1 shared · one timeAdvent Life Sciences LLP 1 shared · one timeSofinnova Investments, Inc. 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
80 dated events
- Sep 16, 2026Xoma no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceXomaVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Vical no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceVicalVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026ViaCyte no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceViaCyteVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Ventritex no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceVentritexVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Theregen no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceTheregenVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Taligen no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceTaligenVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Stereotaxis no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceStereotaxisVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Stentor no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceStentorVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Regeneron no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceRegeneronVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Pacira no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferencePaciraVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026NeoMend no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceNeoMendVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Metavention no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceMetaventionVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026LineaGen no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceLineaGenVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026ISTA no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceISTAVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Intermune no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceIntermuneVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026GeminX no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceGeminXVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Endocyte no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceEndocyteVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Digirad no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceDigiradVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Dendreon no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceDendreonVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026CardioNet no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceCardioNetVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026CalciMedica no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceCalciMedicaVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Altor BioScience no longer listed on Sanderling Management Company, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceAltor BioScienceVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Robert G. McNeil (Founding Partner (September 4, 1943 – July 23, 2021)) no longer on the team page of Sanderling Management Company, LLCPerson leftPeopleInferenceRobert G. McNeilVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Timothy Mills (Managing Director) no longer on the team page of Sanderling Management Company, LLCPerson leftPeopleInferenceTimothy MillsVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026Theregen: acquired by Shire on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026Cylene: acquired by Senwha Biosciuences on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026Aderis: acquired by Schwarz Pharma on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026ViaCyte: acquired by Vertex Pharmaceuticals on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026CardioNet: listed (NASDAQ: BEAT) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactCardioNetVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026Stereotaxis: listed (NASDAQ: STXS) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactStereotaxisVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026Actimis: acquired by Boehringer Ingelheim on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026UltraBridge UltraBridge, Inc.: acquired by CareCentric on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026GeminX: acquired by Cephalon on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026ISTA: listed (NASDAQ: ISTA) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactISTAVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026DepoTech: acquired by SkyePharma on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026Stentor: acquired by Philips on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026Pacira: listed (NASDAQ: PCRX) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactPaciraVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026Naviscan: acquired by CMR Naviscan on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026Dendreon: listed (NASDAQ: DNDN) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactDendreonVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026CalciMedica: listed (NASDAQ: CALC) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactCalciMedicaVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026Xoma: listed (NASDAQ: XOMA) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactXomaVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026Regeneron: listed (NASDAQ: REGN) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactRegeneronVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026Digirad: listed (NASDAQ: DRAD) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactDigiradVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026Endocyte: listed (NASDAQ: ECYT) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactEndocyteVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026Intermune: listed (NASDAQ: ITMN) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactIntermuneVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026NeoMend: acquired by C.R. Bard on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026LineaGen: acquired by Bionano Genomics on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026Altor BioScience: acquired by ImmunityBio on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026Vical: listed (NASDAQ: VICL) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio pagePublic listingExitsFactVicalVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 13, 2026Ventritex: acquired by ST. JUDE MEDICAL on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Sep 13, 2026Taligen: acquired by Alexion Pharmaceuticals on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
- Mar 30, 2024Sanderling Venture Partners IV Co-Investment Fund, L.P. no longer reported on Form ADV by Sanderling Management Company, LLC
- Mar 30, 2024Sanderling Venture Partners IV, L.P. no longer reported on Form ADV by Sanderling Management Company, LLCFund no longer reportedFundsInferenceSanderling Venture Partners IV, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2024Sanderling IV Biomedical Co-Investment Fund, L.P. no longer reported on Form ADV by Sanderling Management Company, LLC
- Mar 30, 2024Sanderling IV [feri Trust] Venture Partners no longer reported on Form ADV by Sanderling Management Company, LLCFund no longer reportedFundsInferenceSanderling IV [feri Trust] Venture PartnersSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2024Sanderling IV Biomedical, L.P. no longer reported on Form ADV by Sanderling Management Company, LLCFund no longer reportedFundsInferenceSanderling IV Biomedical, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2024Revelation-Sanderling, LLC no longer reported on Form ADV by Sanderling Management Company, LLCFund no longer reportedFundsInferenceRevelation-Sanderling, LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 4, 2022Robert Gordon Mcneil (Managing Director) no longer on Schedule A of Sanderling Management Company, LLC
- Apr 29, 2020Peter C. M. Macwilliams (Managing Director) no longer on Schedule A of Sanderling Management Company, LLC
- Dec 1, 2017Peter C. M. Macwilliams joined Schedule A of Sanderling Management Company, LLC as Managing Director
- Mar 21, 2017Sanderling Ventures VII Annex Fund, LP first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $4,798,428Fund first reported on Form ADVFundsFactSanderling Ventures VII Annex Fund, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 21, 2016Revelation-Sanderling, LLC first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $141,598,705Fund first reported on Form ADVFundsFactRevelation-Sanderling, LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2014Sanderling Ventures VII (canada), L.P. first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $4,117,397Fund first reported on Form ADVFundsFactSanderling Ventures VII (canada), L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 27, 2013Sanderling Ventures VII, L.P. first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund)Fund first reported on Form ADVFundsFactSanderling Ventures VII, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 27, 2013Sanderling Venture Partners II, L.P. no longer reported on Form ADV by Sanderling Management Company, LLCFund no longer reportedFundsInferenceSanderling Venture Partners II, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling V Limited Partnership first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $15,439,394Fund first reported on Form ADVFundsFactSanderling V Limited PartnershipSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling VI Beteiligungs Gmbh & Co. Kg first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $7,490,609Fund first reported on Form ADVFundsFactSanderling VI Beteiligungs Gmbh & Co. KgSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling VI Limited Partnership first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $8,972,706Fund first reported on Form ADVFundsFactSanderling VI Limited PartnershipSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling V Strategic Exit Fund, L.P. first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $40,877,218Fund first reported on Form ADVFundsFactSanderling V Strategic Exit Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling Venture Partners II, L.P. first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $641,403Fund first reported on Form ADVFundsFactSanderling Venture Partners II, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling IV Limited Partnership first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $2,140,372Fund first reported on Form ADVFundsFactSanderling IV Limited PartnershipSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling Venture Partners IV, L.P. first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $6,041,532Fund first reported on Form ADVFundsFactSanderling Venture Partners IV, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling IV [feri Trust] Venture Partners first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $546,138Fund first reported on Form ADVFundsFactSanderling IV [feri Trust] Venture PartnersSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling Ventures Partners VI Co-Investment Fund, L.P. first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $172,092,714Fund first reported on Form ADVFundsFactSanderling Ventures Partners VI Co-Investment Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling Venture Partners VI, L.P. first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $310,206,643Fund first reported on Form ADVFundsFactSanderling Venture Partners VI, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling V Beteiligungs Gmbh & Co. Kg first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $13,927,354Fund first reported on Form ADVFundsFactSanderling V Beteiligungs Gmbh & Co. KgSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling V Biomedical Co-Investment Fund, L.P. first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $35,210,943Fund first reported on Form ADVFundsFactSanderling V Biomedical Co-Investment Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling Venture Partners V, L.P. first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $89,767,974Fund first reported on Form ADVFundsFactSanderling Venture Partners V, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling V Biomedical, LP first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $21,803,918Fund first reported on Form ADVFundsFactSanderling V Biomedical, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Sanderling IV Biomedical Co-Investment Fund, L.P. first reported on Form ADV by Sanderling Management Company, LLC (Venture Capital Fund), GAV $2,935,536Fund first reported on Form ADVFundsFactSanderling IV Biomedical Co-Investment Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 15, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $177M across 23 vehicles
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $81M across 16 vehicles
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $81M across 8 vehicles
Evidence
57 observations from 3 sources